Verenium Corporation Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 5 Calls Today's Calls

Call Details Verenium Corporation Earnings Conference Call (Q1 2008) Mon, May 5, 2008, 4:30 pm Eastern Listen to the archived event audio About Verenium Corporation (NasdaqGM:VRNM) Verenium Corporation, together with its subsidiaries, engages in the development and production of specialty enzyme products, and production and commercialization of biofuels. It operates in two segments, Biofuels and Specialty Enzymes. The Biofuels segment focuses on the production and commercialization of biofuels, primarily ethanol from cellulosic biomass. The Specialty Enzymes segment develops customized enzymes for use in alternative fuels, specialty industrial processes, and animal nutrition and health markets. Its products include Fuelzyme—LF, an alpha amylase enzyme, designed to improve the efficiency and economics of ethanol production from corn and other grain, or starch sources; Purifine enzyme for biodiesel applications; Amylase-T Transgenic Corn Amylase; Fuelzyme-CX enzymes for cellulosic ethanol; Purifine for edible oils; Luminase for pulp and paper processing; Phyzyme XP; Quantum phytase; Bayovac SRS that is designed to prevent disease in farmed Atlantic salmon; and Phytase-T, which supplements Quantum phytase. The company has strategic collaborations with Syngenta AG for the discovery and development of a range of novel enzymes; Bunge Oils, Inc. to discover and develop novel enzymes for the production of edible oil products; Cargill Health and Food Technologies to discover and develop novel enzymes for the production of a proprietary Cargill product; BASF AG to develop biocatalytic enzymes; DuPont Bio for the production of ethanol and other chemical products from corn biomass; and Bayer Animal Health to develop and market products to prevent infectious diseases in fish. It operates in North America, South America, Europe, Asia, and the Middle East. The company was founded in 1992 under the name Industrial Genome Sciences, Inc. and changed its name to Diversa Corporation in 1997. Further, it changed its name to Verenium Corporation in 2007. The company is headquartered in Cambridge, Massachusetts. More Info: Quote | Profile | Reports | Research | Insider | Financials | Analyst Ratings